Cargando…
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma
It has been commonly found that in patients presenting Pancreatic Ductal Adenocarcinoma (PDAC), after a period of satisfactory response to standard treatments, the tumor becomes non-responsive and patient death quickly follows. This phenomenon is mainly due to the rapid and uncontrolled development...
Autores principales: | Molejon, Maria Inés, Tellechea, Juan Ignacio, Loncle, Celine, Gayet, Odile, Gilabert, Marine, Duconseil, Pauline, Lopez-Millan, Maria Belen, Moutardier, Vincent, Gasmi, Mohamed, Garcia, Stephane, Turrini, Olivier, Ouaissi, Mehdi, Poizat, Flora, Dusetti, Nelson, Iovanna, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480689/ https://www.ncbi.nlm.nih.gov/pubmed/25797268 |
Ejemplares similares
-
Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence
por: Molejon, Maria Inés, et al.
Publicado: (2015) -
A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor
por: Gayet, Odile, et al.
Publicado: (2014) -
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT
por: Barraud, Marine, et al.
Publicado: (2016) -
Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
por: Bian, Benjamin, et al.
Publicado: (2017) -
Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
por: Nicolle, Rémy, et al.
Publicado: (2017)